Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track AZTR with free AI briefings, catalyst countdowns, and dilution alerts.

AZTR · Azitra, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$3.8M Cash on Hand
3.6mo Cash Runway
Follow AZTR by email Get an email when AZTR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AZTR, unsubscribe in one click. Privacy

📣 What AZTR Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
ATR-04 Epidermal Growth Factor Phase 1/2 · NCT04731259 Withdrawn
Staphylococcus epidermidis Strain Topical… EGFR Inhibitor-associated Rash Phase 1/2 · NCT06830863 Recruiting
ATR12-351 Netherton Syndrome Phase 1 · NCT06137157 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AZTR holds $3.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.1M/quarter from operations, an estimated runway of 3.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 80 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AZTR files for a raise →

👥 Who Owns AZTR

Insiders 73.8% Other 5%+ holders 26.2% Institutions 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
Nantahala Capital Management, LLC Institution (13G, 5%+) 6,480,584 106.93% 2026-06-30
Dauntless Investment Group, LLC 5%+ holder (13G) 5,804,636 95.78% 2026-06-24
NANTAHALA CAPITAL PARTNERS LIMITED PARTN 5%+ holder (13G) 5,448,213 89.90% 2026-06-30
Francisco D. Salva
President and CEO, Director · +8.41M options
Insider 4,086,291 67.43% 2026-06-16
Stonepine Capital Management, LLC Institution (13G, 5%+) 1,744,339 28.78% 2026-06-16
Alumni Capital LP 5%+ holder (13G) 1,132,622 18.69% 2025-11-25
Travis Whitfill
Chief Operating Officer, Director · +88,024 options
Insider 334,500 5.52% 2024-02-13
Young Pharmaceuticals, Inc. 5%+ holder (13D) 316,300 5.22% 2026-11-06
Norm Staskey
Chief Financial Officer · +50,539 options
Insider 51,100 0.84% 2024-03-29

Share count 6,060,435 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full AZTR picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AZTR and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.